levofloxacin has been researched along with nortriptyline in 11 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (nortriptyline) | Trials (nortriptyline) | Recent Studies (post-2010) (nortriptyline) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 2,289 | 517 | 327 |
| Protein | Taxonomy | levofloxacin (IC50) | nortriptyline (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.0032 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.347 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.095 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.17 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.366 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 1.9 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.95 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.082 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.17 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.047 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.1015 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.019 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.171 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.539 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0032 | |
| Histamine H2 receptor | Homo sapiens (human) | 2.334 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.273 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.051 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.016 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.019 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.17 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.013 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.17 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.05 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.179 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.136 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.554 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 10 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.678 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for levofloxacin and nortriptyline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for levofloxacin and nortriptyline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |